Motley Fool Staff
the_motley_fool
Recent Articles by Motley Fool Staff

Apr 7, 2016
by Motley Fool Staff
Could Washington Throw Out Medivation's Xtandi Patents?
Members of Congress are lobbying for the NIH to use a rarely invoked law to invalidate exclusivity on Xtandi's patents, based on the idea that the high prices Medivation charges for it are harming American consumers.

Apr 5, 2016
by Motley Fool Staff
Are Portola Pharmaceuticals' Hopes Dashed? Maybe Not.
Trial results for its anticoagulant Betrixaban were a mixed bag, but the drug could still find its way to market. And if not, another drug with a FDA-approval decision date in August could still move the needle at Portola.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.